Guangzhou Wondfo Biotech Co Ltd
SZSE:300482

Watchlist Manager
Guangzhou Wondfo Biotech Co Ltd Logo
Guangzhou Wondfo Biotech Co Ltd
SZSE:300482
Watchlist
Price: 24.29 CNY -6.22% Market Closed
Market Cap: 11.6B CNY
Have any thoughts about
Guangzhou Wondfo Biotech Co Ltd?
Write Note

Guangzhou Wondfo Biotech Co Ltd
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Guangzhou Wondfo Biotech Co Ltd
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Guangzhou Wondfo Biotech Co Ltd
SZSE:300482
Accounts Receivables
ÂĄ826.5m
CAGR 3-Years
16%
CAGR 5-Years
18%
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Accounts Receivables
ÂĄ41.4m
CAGR 3-Years
-2%
CAGR 5-Years
10%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Accounts Receivables
ÂĄ1.1B
CAGR 3-Years
13%
CAGR 5-Years
-6%
CAGR 10-Years
6%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Accounts Receivables
ÂĄ4B
CAGR 3-Years
28%
CAGR 5-Years
17%
CAGR 10-Years
N/A
J
Jafron Biomedical Co Ltd
SZSE:300529
Accounts Receivables
ÂĄ72m
CAGR 3-Years
-36%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Accounts Receivables
ÂĄ3.3B
CAGR 3-Years
67%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Guangzhou Wondfo Biotech Co Ltd
Glance View

Market Cap
11.5B CNY
Industry
Health Care

Guangzhou Wondfo Biotech Co., Ltd. engages in the manufacture and sale of biochemical reagents, medical products and diagnostic test kits. The company is headquartered in Guangzhou, Guangdong and currently employs 3,411 full-time employees. The company went IPO on 2015-06-30. According to the testing result, the Company' products can be divided into qualitative testing products and quantitative testing products. According to the usage, the Company' products include pregnancy testing series, infectious diseases testing series, drugs (drug abuse) testing series and chronic disease testing series. The firm's products are used in POCT, clinical test, field test and personal health management, among others.

Intrinsic Value
42.67 CNY
Undervaluation 43%
Intrinsic Value
Price

See Also

What is Guangzhou Wondfo Biotech Co Ltd's Accounts Receivables?
Accounts Receivables
826.5m CNY

Based on the financial report for Sep 30, 2024, Guangzhou Wondfo Biotech Co Ltd's Accounts Receivables amounts to 826.5m CNY.

What is Guangzhou Wondfo Biotech Co Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
18%

Over the last year, the Accounts Receivables growth was 46%. The average annual Accounts Receivables growth rates for Guangzhou Wondfo Biotech Co Ltd have been 16% over the past three years , 18% over the past five years .

Back to Top